CellRight, which produces verified osteobiologics for use in orthopedic, spine and foot and ankle procedures, enhances the healing opportunities of defects caused by trauma and disease.
The multi-year commitment will give surgeons access to verified osteobiologics and advanced surgical instrumentation and techniques to help influence better patient outcomes.
“This long-term distribution agreement will allow physicans and patients better access to CellRight’s orthobiologics through the Arthrex network,” said Jesus Hernandez, CEO for CellRight Technologies. "Our shared vision of offering surgeons total solutions which can positively impact patient outcomes solidifies the decision of both companies to work together.”
Steve Couldwell, CEO Tissue Regenix Group plc, commented: “This is a flagship distribution agreement for CellRight and the wider Tissue Regenix Group. It highlights the value of strategic partnerships with prestigious companies in this space. We look forward to working with Arthrex to bring the CellRight product portfolio to an extended network of healthcare professionals.”
Tissue Regenix is a regenerative medicine company, formed in 2006 in a spin-out from the University of Leeds, United Kingdom. The company's patented decellularisation (dCELL) technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
Learn more about dCELL in the video below:
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States: Tissue Regenix Wound Care Inc., rebranded TRX BioSurgery in February 2018. In January 2016 the company established joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.